PUNE, India, May 14, 2018 /PRNewswire/ --

According to a new market research report "Immunoassay Market by Product & Service (Reagents & Kits, Analyzers, Software), Technology (ELISA, Rapid Test), Platform (Radioimmunoassay), Specimen, Application (Infectious Diseases, Oncology, Cardiology), End User (Hospitals) - Global Forecast to 2023", published by MarketsandMarkets™, the market is expected to reach USD 27.15 Billion by 2023 from USD 20.19 Billion in 2018, at a CAGR of 6.1%.

     (Logo: https://mma.prnewswire.com/media/660509/MarketsandMarkets_Logo.jpg )

Browse 293 market data Tables and 50 Figures spread through 344 Pages and in-depth TOC on "Immunoassay Market"

https://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html

Early buyers will receive 10% customization on this report 

The increasing incidence of chronic and infectious diseases, technological advancements in immunoassay instruments and introduction of novel automated systems, and growth in the biotechnology and biopharmaceutical industries are some the major factors driving the growth of this market.

By product and service, the reagents and kits segment commanded the largest share of the market in 2017 

On the basis product and service, this market is classified into reagents and kits, analyzers, and software and services. In 2017, the reagents and kits segment accounted for the largest share of the Immunoassays Market. The large share of this segment can primarily be attributed to the requirement of the repeat purchase of kits and reagents, coupled with the increasing number of immunoassay tests being performed across the globe as a result of the rising incidence of chronic and infectious diseases.

The chemiluminescence immunoassays (CLIAs) segment led the Immunoassays Market in 2017 

By platform, this market is classified into CLIAs, radioimmunoassay (RIAs), colorimetric immunoassays (CIs), fluorescence immunoassays (FIAs), and other platforms. The CLIAs segment accounted for the largest share of the Immunoassays Market in 2017. The large share of this segment can primarily be attributed to the low cost and high sensitivity of CLIA-based tests.

Ask for PDF Brochure @ https://www.marketsandmarkets.com/pdfdownload.asp?id=436

By technology, the enzyme-linked immunosorbent assays (ELISA) segment accounted for the largest share of the market in 2017 

On the basis of technology, the Immunoassays Market is segmented into ELISA, rapid tests, western blotting, enzyme-linked immunospot (ELISPOT), immuno-PCR, and other immunoassay technologies. The ELISA segment accounted for the largest share of the Immunoassays Market in 2017. The large share of this segment can primarily be attributed to the increasing use of immunoassay tests in cancer, infectious diseases, and therapeutic drug level monitoring.

North America held the largest share of the market in 2017 

Based on region, the Immunoassay Market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America dominated the market in 2017. The large share of this regional segment is attributed to the increasing incidence of chronic diseases and improved healthcare infrastructure.

Key players in the Immunoassays Market include Roche (Switzerland), Abbott Laboratories (US), Siemens (Germany), Danaher Corporation (US), Sysmex Corporation (Japan), bioMérieux (France), Ortho Clinical Diagnostics (US), DiaSorin (Italy), QIAGEN (Netherlands), Thermo Fisher Scientific (US), Becton, Dickinson and Company (US), Merck (Germany), Bio-Rad Laboratories (US), Agilent Technologies (US), PerkinElmer (US), Quidel Corporation (US), Bio-Techne Corporation (US), and Mindray (China).

Know more about the Immunoassay Market: 

https://www.marketsandmarkets.com/Market-Reports/immunoassay-market-436.html

About MarketsandMarkets™  

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "RT" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Salgarkar
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com

Connect with us on LinkedIn @ http://www.linkedin.com/company/marketsandmarkets

SOURCE MarketsandMarkets